By a News Reporter-Staff News Editor at Gene Therapy Weekly -- Investigators discuss new findings in Biotechnology. According to news reporting from Chapel Hill, North Carolina, by NewsRx journalists, research stated, "It is hoped that the use of gene transfer technology to treat both monogenetic and acquired diseases may soon become a common therapy option in medicine. For gene therapy to achieve this objective, any gene delivery method will have to meet several criteria, including ease of manufacturing, efficient gene transfer to target tissue, long-term gene expression to alleviate the disease, and most importantly safety in patients."
The news correspondents obtained a quote from the research from the University of North Carolina, "Viral vectors are an attractive choice for use in gene therapy protocols due to their relative efficiency in gene delivery. Since there is inherent risk in using viruses, investigators in the gene therapy community have devoted extensive efforts toward reengineering viral vectors for enhance safety. Here we review the approaches and technologies that are being evaluated for the use of recombinant vectors based upon adeno-associated virus (AAV) in the treatment of a variety of human diseases. AAV is currently the only known human DNA virus that is non-pathogenic and AAV-based vectors are classified as Risk Group 1 agents for all laboratory and animal studies carried out in the US."
According to the news reporters, the research concluded: "Although its apparent safety in natural infection and animals appears well documented, we examine the accumulated knowledge on the biology and vectorology of AAV, lessons learned from gene therapy clinical trials, and how this information is impacting current vector design and manufacturing with an overall emphasis on biosafety."
For more information on this research see: Biosafety of Recombinant Adeno-associated Virus Vectors. Current Gene Therapy, 2013;13(6):434-452. Current Gene Therapy can be contacted at: Bentham Science Publ Ltd, Executive Ste Y-2, PO Box 7917, Saif Zone, 1200 Br Sharjah, U Arab Emirates. (Bentham Science Publishers - www.benthamscience.com; Current Gene Therapy - www.benthamscience.com/cgt/index.htm)
Our news journalists report that additional information may be obtained by contacting D.J. Dismuke, University of North Carolina, Dept. of Pharmacol, Chapel Hill, NC 27599, United States. Additional authors for this research include L. Tenenbaum and R.J. Samulski (see also Biotechnology).
Keywords for this news article include: Biotechnology, Viruses, Virology, Chapel Hill, Gene Therapy, United States, North Carolina, Bioengineering, Adeno-Associated Virus, North and Central America, Clinical Trials and Studies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC